daunorubicin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, daunorubicin derivatives 786 20830-81-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • daunorubicin
  • acetyladriamycin
  • cerubidin
  • daunoblastina
  • daunomycine
  • daunorubicine
  • Leukaemomycin C
  • rubidomycin
  • daunorubicin hydrochloride
  • daunorubicin citrate
  • daunorubicin HCl
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
  • Molecular weight: 527.53
  • Formula: C27H29NO10
  • CLOGP: 0.84
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 5
  • TPSA: 185.84
  • ALOGS: -2.93
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.04 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.05 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 32.05 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 47.57 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14.24 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 19, 1979 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 677.00 21.17 378 12017 94249 46579418
Hypofibrinogenaemia 310.46 21.17 69 12326 1001 46672666
Posterior reversible encephalopathy syndrome 235.49 21.17 103 12292 15038 46658629
Sepsis 189.99 21.17 206 12189 135808 46537859
Haematotoxicity 175.85 21.17 67 12328 6866 46666801
Neutropenia 164.47 21.17 196 12199 143008 46530659
Acute myeloid leukaemia 154.50 21.17 78 12317 15700 46657967
Bone marrow failure 137.38 21.17 90 12305 29579 46644088
Hyperbilirubinaemia 118.24 21.17 57 12338 10381 46663286
Thrombocytopenia 101.10 21.17 145 12250 126436 46547231
Mucormycosis 99.43 21.17 33 12362 2259 46671408
Pneumatosis intestinalis 99.34 21.17 32 12363 1993 46671674
Septic shock 88.23 21.17 92 12303 57801 46615866
Blood culture positive 87.75 21.17 36 12359 4476 46669191
Colitis 86.84 21.17 75 12320 37272 46636395
Tumour lysis syndrome 86.47 21.17 41 12354 7195 46666472
Febrile bone marrow aplasia 85.44 21.17 40 12355 6822 46666845
Neutropenic sepsis 84.27 21.17 48 12347 12276 46661391
Second primary malignancy 83.90 21.17 39 12356 6545 46667122
Cardiotoxicity 83.13 21.17 39 12356 6683 46666984
Aplasia 81.55 21.17 32 12363 3544 46670123
Multiple organ dysfunction syndrome 78.47 21.17 82 12313 51628 46622039
Human bocavirus infection 77.16 21.17 18 12377 327 46673340
Neutropenic colitis 76.74 21.17 27 12368 2205 46671462
Clostridium difficile colitis 75.57 21.17 52 12343 18501 46655166
Pancytopenia 74.63 21.17 102 12293 84956 46588711
Pain 73.99 21.17 18 12377 476930 46196737
Leukaemia recurrent 73.79 21.17 23 12372 1286 46672381
Bronchopulmonary aspergillosis 73.18 21.17 37 12358 7459 46666208
Mucosal inflammation 72.40 21.17 69 12326 38907 46634760
Secondary immunodeficiency 71.34 21.17 21 12374 966 46672701
Human herpesvirus 6 infection 67.01 21.17 25 12370 2414 46671253
Disseminated intravascular coagulation 63.00 21.17 47 12348 18958 46654709
Blood bilirubin increased 62.51 21.17 60 12335 34124 46639543
Cerebral venous sinus thrombosis 62.45 21.17 22 12373 1803 46671864
Enterobacter infection 61.73 21.17 22 12373 1865 46671802
Acute respiratory distress syndrome 59.17 21.17 48 12347 21874 46651793
Aspergillus infection 58.60 21.17 31 12364 6859 46666808
Fatigue 57.10 21.17 47 12348 608650 46065017
Arthralgia 56.01 21.17 14 12381 364589 46309078
Pyrexia 55.94 21.17 211 12184 348591 46325076
Venous thrombosis 53.90 21.17 26 12369 4736 46668931
Bacteraemia 53.67 21.17 38 12357 14141 46659526
Venoocclusive disease 53.55 21.17 20 12375 1936 46671731
Bacterial infection 53.52 21.17 40 12355 16176 46657491
Alanine aminotransferase increased 53.24 21.17 89 12306 88362 46585305
Acute myeloid leukaemia recurrent 52.28 21.17 18 12377 1378 46672289
Cerebral venous thrombosis 51.92 21.17 20 12375 2107 46671560
Differentiation syndrome 51.32 21.17 16 12379 895 46672772
Device related infection 50.40 21.17 43 12352 20998 46652669
Hyperglycaemia 50.31 21.17 54 12341 35017 46638650
Drug hypersensitivity 49.75 21.17 4 12391 243821 46429846
Hepatic failure 48.90 21.17 52 12343 33364 46640303
Venoocclusive liver disease 47.48 21.17 23 12372 4228 46669439
Malaise 46.63 21.17 15 12380 331217 46342450
Gastroenteritis norovirus 46.44 21.17 17 12378 1556 46672111
Haemophagocytic lymphohistiocytosis 45.28 21.17 28 12367 8314 46665353
Fall 44.42 21.17 16 12379 329081 46344586
Herpes simplex 43.72 21.17 26 12369 7197 46666470
Neurotoxicity 43.41 21.17 33 12362 13684 46659983
Pneumonia moraxella 42.76 21.17 8 12387 45 46673622
Respiratory distress 42.05 21.17 47 12348 31869 46641798
Hypotension 41.67 21.17 146 12249 232443 46441224
Staphylococcal sepsis 40.17 21.17 25 12370 7507 46666160
Superior sagittal sinus thrombosis 39.81 21.17 13 12382 845 46672822
Pulse waveform abnormal 39.47 21.17 8 12387 72 46673595
Ankle brachial index decreased 39.38 21.17 8 12387 73 46673594
Carotid intima-media thickness increased 38.90 21.17 8 12387 78 46673589
Ileus paralytic 38.32 21.17 20 12375 4303 46669364
Acute lymphocytic leukaemia recurrent 38.31 21.17 16 12379 2079 46671588
Blast crisis in myelogenous leukaemia 37.55 21.17 11 12384 497 46673170
Osteonecrosis 37.55 21.17 40 12355 25704 46647963
Enteritis 37.49 21.17 23 12372 6732 46666935
Acute lymphocytic leukaemia 37.12 21.17 17 12378 2756 46670911
Enterococcal infection 36.78 21.17 23 12372 6964 46666703
Rhinovirus infection 35.64 21.17 18 12377 3618 46670049
Myelodysplastic syndrome 35.38 21.17 31 12364 15680 46657987
Stenotrophomonas infection 35.20 21.17 14 12381 1606 46672061
Hypoxia 35.03 21.17 55 12340 51783 46621884
Hepatotoxicity 34.97 21.17 38 12357 24971 46648696
Minimal residual disease 34.74 21.17 7 12388 61 46673606
Streptococcal bacteraemia 34.34 21.17 13 12382 1306 46672361
Pseudomonas infection 34.29 21.17 25 12370 9733 46663934
Ejection fraction decreased 33.75 21.17 32 12363 17905 46655762
Respiratory failure 33.25 21.17 76 12319 94740 46578927
Neoplasm recurrence 33.19 21.17 15 12380 2358 46671309
Nausea 32.95 21.17 85 12310 687369 45986298
Urinary tract infection 32.74 21.17 9 12386 220257 46453410
Pleural effusion 31.91 21.17 69 12326 82883 46590784
Drug ineffective 30.82 21.17 86 12309 677752 45995915
Aborted pregnancy 30.70 21.17 6 12389 44 46673623
Pneumonia fungal 30.59 21.17 17 12378 4143 46669524
Leukopenia 29.97 21.17 60 12335 68283 46605384
Blood fibrinogen decreased 29.91 21.17 10 12385 700 46672967
Cerebral haemorrhage 29.46 21.17 37 12358 28334 46645333
Coagulopathy 29.23 21.17 30 12365 18469 46655198
Depression 29.22 21.17 5 12390 170099 46503568
Pseudomonal sepsis 29.10 21.17 13 12382 1989 46671678
Pruritus 29.09 21.17 14 12381 242338 46431329
Dizziness 28.57 21.17 29 12366 340385 46333282
Genotoxicity 28.13 21.17 5 12390 20 46673647
Acute promyelocytic leukaemia 27.36 21.17 10 12385 911 46672756
Chronic myeloid leukaemia recurrent 27.02 21.17 7 12388 199 46673468
Dyspnoea 26.81 21.17 61 12334 515487 46158180
Pancreatitis acute 26.73 21.17 33 12362 24839 46648828
Left ventricular dysfunction 26.71 21.17 22 12373 10233 46663434
Dysplasia 26.67 21.17 9 12386 648 46673019
Clostridium test positive 26.52 21.17 12 12383 1892 46671775
Pulmonary oedema 26.26 21.17 48 12347 51057 46622610
Leukoerythroblastosis 26.20 21.17 7 12388 225 46673442
Pancreatitis necrotising 26.13 21.17 11 12384 1458 46672209
Pulmonary haemorrhage 25.93 21.17 18 12377 6487 46667180
Renal replacement therapy 25.91 21.17 5 12390 34 46673633
Alpha haemolytic streptococcal infection 25.85 21.17 9 12386 712 46672955
Ureaplasma infection 25.57 21.17 8 12387 453 46673214
Pseudomonas test positive 25.55 21.17 9 12386 737 46672930
Hemiparesis 25.49 21.17 29 12366 20040 46653627
Geotrichum infection 25.38 21.17 8 12387 464 46673203
Haemodynamic instability 25.36 21.17 19 12376 7706 46665961
Cardiomyopathy 25.27 21.17 26 12369 16047 46657620
Stem cell transplant 24.18 21.17 11 12384 1755 46671912
Bacillus infection 23.61 21.17 7 12388 330 46673337
Candida infection 23.08 21.17 29 12366 22211 46651456
Dialysis 22.85 21.17 20 12375 10096 46663571
Transverse sinus thrombosis 22.51 21.17 8 12387 672 46672995
Inappropriate antidiuretic hormone secretion 22.51 21.17 23 12372 14079 46659588
Hepatocellular injury 22.30 21.17 33 12362 29489 46644178
Enterocolitis 22.12 21.17 16 12379 6152 46667515
Otitis externa 21.82 21.17 10 12385 1623 46672044
Breakthrough pain 21.75 21.17 9 12386 1143 46672524
Cholestasis 21.68 21.17 31 12364 26862 46646805
Anal ulcer 21.62 21.17 7 12388 443 46673224

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 613.34 18.75 455 13324 106238 29832461
Hypofibrinogenaemia 307.90 18.75 83 13696 1562 29937137
Haematotoxicity 259.38 18.75 100 13679 6070 29932629
Posterior reversible encephalopathy syndrome 175.86 18.75 84 13695 8623 29930076
Neutropenia 166.54 18.75 247 13532 128293 29810406
Aspergillus infection 166.04 18.75 85 13694 10129 29928570
Sepsis 153.15 18.75 255 13524 146140 29792559
Bone marrow failure 133.16 18.75 110 13669 29675 29909024
Septic shock 128.25 18.75 152 13627 63455 29875244
Colitis 119.72 18.75 105 13674 30715 29907984
Bronchopulmonary aspergillosis 119.60 18.75 73 13706 12211 29926488
Oesophageal stenosis 117.03 18.75 39 13740 1544 29937155
Acute myeloid leukaemia 116.77 18.75 83 13696 17923 29920776
Hypertriglyceridaemia 110.59 18.75 60 13719 8038 29930661
Mucormycosis 106.89 18.75 51 13728 5217 29933482
Tumour lysis syndrome 106.43 18.75 69 13710 12816 29925883
Hyperbilirubinaemia 102.77 18.75 75 13704 16867 29921832
Leukaemia recurrent 94.07 18.75 33 13746 1528 29937171
Blood fibrinogen decreased 83.73 18.75 27 13752 962 29937737
Neutropenic colitis 82.61 18.75 33 13746 2197 29936502
Multiple organ dysfunction syndrome 81.94 18.75 122 13657 63365 29875334
Osteonecrosis 79.27 18.75 63 13716 16072 29922627
Hepatotoxicity 74.83 18.75 64 13715 18081 29920618
Cerebral venous thrombosis 74.37 18.75 22 13757 585 29938114
Pancytopenia 74.16 18.75 137 13642 84915 29853784
Acute myeloid leukaemia recurrent 68.21 18.75 26 13753 1526 29937173
Acute lymphocytic leukaemia recurrent 63.98 18.75 29 13750 2638 29936061
Glioma 63.95 18.75 17 13762 302 29938397
Pyrexia 62.50 18.75 284 13495 294205 29644494
Mucosal inflammation 59.91 18.75 72 13707 30422 29908277
Fatigue 58.42 18.75 38 13741 320635 29618064
Febrile bone marrow aplasia 56.36 18.75 39 13740 8058 29930641
Fungal infection 56.12 18.75 48 13731 13552 29925147
Venoocclusive disease 55.37 18.75 26 13753 2564 29936135
Bacteraemia 54.41 18.75 50 13729 15510 29923189
Differentiation syndrome 53.02 18.75 20 13759 1140 29937559
Superior sagittal sinus thrombosis 50.27 18.75 14 13765 298 29938401
Death 49.59 18.75 55 13724 357228 29581471
Multiple-drug resistance 49.29 18.75 25 13754 2916 29935783
Central nervous system fungal infection 47.64 18.75 13 13766 256 29938443
Blood bilirubin increased 46.63 18.75 70 13709 36566 29902133
Pneumonia fungal 46.58 18.75 30 13749 5503 29933196
Leukoencephalopathy 42.07 18.75 25 13754 3977 29934722
Systemic candida 42.01 18.75 22 13757 2742 29935957
Aplasia 41.87 18.75 25 13754 4012 29934687
Hypoxia 40.29 18.75 76 13703 47778 29890921
Acute lymphocytic leukaemia 39.82 18.75 22 13757 3050 29935649
Hepatic steatosis 37.69 18.75 40 13739 14753 29923946
T-cell type acute leukaemia 37.33 18.75 10 13769 183 29938516
Inappropriate antidiuretic hormone secretion 36.66 18.75 35 13744 11387 29927312
Respiratory failure 36.10 18.75 115 13664 100527 29838172
Dizziness 35.53 18.75 23 13756 194886 29743813
Acute monocytic leukaemia 35 18.75 11 13768 360 29938339
Malaise 34.30 18.75 17 13762 166945 29771754
Myocardial infarction 34.06 18.75 8 13771 125617 29813082
Hypoalbuminaemia 33.73 18.75 33 13746 11059 29927640
Personality change due to a general medical condition 33.19 18.75 7 13772 42 29938657
Candida endophthalmitis 32.78 18.75 8 13771 99 29938600
Glioblastoma multiforme 32.76 18.75 13 13766 850 29937849
Congenital pneumonia 32.56 18.75 8 13771 102 29938597
Disseminated intravascular coagulation 32.04 18.75 45 13734 22126 29916573
Coagulopathy 32.04 18.75 41 13738 18446 29920253
Gallbladder empyema 31.90 18.75 7 13772 52 29938647
Neoplasm recurrence 31.66 18.75 16 13763 1851 29936848
Acute respiratory distress syndrome 31.51 18.75 46 13733 23426 29915273
Device related infection 31.49 18.75 39 13740 16976 29921723
Meningeal neoplasm 30.91 18.75 7 13772 61 29938638
Depression 30.77 18.75 3 13776 90434 29848265
Arthralgia 30.76 18.75 12 13767 135779 29802920
Intussusception 30.73 18.75 11 13768 540 29938159
Large intestine infection 30.72 18.75 14 13765 1289 29937410
Pseudomonas test positive 30.71 18.75 13 13766 1003 29937696
Mucosal infection 30.65 18.75 9 13770 233 29938466
Bacterial sepsis 30.29 18.75 22 13757 4904 29933795
Haemophagocytic lymphohistiocytosis 29.53 18.75 29 13750 9762 29928937
Sweat gland tumour 29.50 18.75 10 13769 417 29938282
Neutropenic sepsis 29.33 18.75 31 13748 11378 29927321
Diarrhoea 28.90 18.75 70 13709 334033 29604666
Stomatitis 28.67 18.75 57 13722 37222 29901477
Venoocclusive liver disease 28.63 18.75 24 13755 6589 29932110
Respiratory distress 28.53 18.75 53 13726 32919 29905780
Overdose 28.17 18.75 3 13776 84334 29854365
Non-alcoholic steatohepatitis 27.33 18.75 11 13768 746 29937953
Pulmonary haemorrhage 26.82 18.75 27 13752 9365 29929334
Asthenia 25.53 18.75 39 13740 221251 29717448
Systemic mycosis 25.35 18.75 12 13767 1204 29937495
Blood culture positive 23.70 18.75 19 13760 4900 29933799
Hip deformity 23.58 18.75 6 13773 89 29938610
Ileus paralytic 23.43 18.75 20 13759 5628 29933071
Clostridium difficile colitis 23.20 18.75 29 13750 12739 29925960
Acute promyelocytic leukaemia 23.00 18.75 9 13770 567 29938132
Lower respiratory tract infection fungal 22.77 18.75 9 13770 582 29938117
Prothrombin level abnormal 22.60 18.75 6 13773 106 29938593
Antithrombin III decreased 22.48 18.75 8 13771 386 29938313
Enterococcal sepsis 22.47 18.75 12 13767 1556 29937143
Thrombocytopenia 22.38 18.75 123 13656 136921 29801778
Enamel anomaly 22.24 18.75 6 13773 113 29938586
Candida infection 21.92 18.75 31 13748 15331 29923368
Central nervous system leukaemia 21.50 18.75 7 13772 257 29938442
Fungal sepsis 21.04 18.75 9 13770 712 29937987
Neurotoxicity 20.92 18.75 28 13751 13154 29925545
Cerebral venous sinus thrombosis 20.42 18.75 7 13772 302 29938397
Pain 20.30 18.75 30 13749 172611 29766088
Low birth weight baby 20.22 18.75 19 13760 6057 29932642
Intracranial pressure increased 20.13 18.75 15 13764 3475 29935224
Intracranial tumour haemorrhage 20.10 18.75 7 13772 317 29938382
Fall 20.06 18.75 33 13746 181839 29756860
Appendicitis 20.04 18.75 19 13760 6125 29932574
Weight decreased 20.01 18.75 24 13755 150897 29787802
Thymus enlargement 19.92 18.75 5 13774 70 29938629
Myelodysplastic syndrome 19.89 18.75 33 13746 18745 29919954
Recurrent cancer 19.71 18.75 10 13769 1166 29937533
Rash 19.20 18.75 37 13742 191852 29746847
Gamma-glutamyltransferase increased 19.20 18.75 42 13737 29308 29909391
Leukopenia 19.04 18.75 63 13716 56096 29882603
Stem cell transplant 19.04 18.75 12 13767 2119 29936580
Sinus tachycardia 18.83 18.75 29 13750 15475 29923224
Skin toxicity 18.82 18.75 14 13765 3235 29935464
Enterococcal infection 18.79 18.75 21 13758 8203 29930496

Pharmacologic Action:

SourceCodeDescription
ATC L01DB02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Anthracyclines and related substances
ATC L01XY01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Combinations of antineoplastic agents
FDA CS M0028312 Anthracyclines
FDA MoA N0000000176 Topoisomerase Inhibitors
FDA EPC N0000175414 Anthracycline Topoisomerase Inhibitor
MeSH PA D000903 Antibiotics, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D059005 Topoisomerase II Inhibitors
CHEBI has role CHEBI:35610 cytostatic

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute lymphoid leukemia indication 91857003 DOID:9952
Acute myeloid leukemia, disease indication 91861009
Erythroleukemia, FAB M6 indication 93451002
Kaposi's sarcoma indication 109385007
Acute promyelocytic leukemia, FAB M3 indication 110004001
Acute monocytic/monoblastic leukemia indication 413442004
Nephroblastoma off-label use 302849000 DOID:2154
Neuroblastoma off-label use 432328008 DOID:769
Mycosis contraindication 3218000 DOID:1564
Pericarditis contraindication 3238004 DOID:1787
Ventricular tachycardia contraindication 25569003
Viral disease contraindication 34014006 DOID:934
Hyperuricemia contraindication 35885006 DOID:1920
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Epilepsy contraindication 84757009 DOID:1826
Cardiomyopathy contraindication 85898001 DOID:0050700
Bacterial infectious disease contraindication 87628006
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Granulocytopenic disorder contraindication 417672002
Protozoal Infection contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.85 acidic
pKa2 9.79 acidic
pKa3 11.6 acidic
pKa4 8.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS March 30, 2024 NEW PATIENT POPULATION
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS Aug. 3, 2024 TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
100MG;44MG VYXEOS CELATOR PHARMS N209401 Aug. 3, 2017 RX POWDER INTRAVENOUS March 30, 2028 TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
DNA topoisomerase 2-alpha Enzyme INHIBITOR WOMBAT-PK CHEMBL
Multidrug resistance-associated protein 6 Transporter WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
72 kDa type IV collagenase Enzyme IC50 5.72 CHEMBL
ORF 73 Unclassified AC50 5.63 CHEMBL

External reference:

IDSource
4019704 VUID
N0000147796 NUI
D01264 KEGG_DRUG
371770-68-2 SECONDARY_CAS_RN
4018061 VANDF
4019704 VANDF
C0011015 UMLSCUI
CHEBI:41977 CHEBI
DM1 PDB_CHEM_ID
30323 PUBCHEM_CID
CHEMBL178 ChEMBL_ID
CHEMBL1200475 ChEMBL_ID
CHEMBL1563 ChEMBL_ID
DB00694 DRUGBANK_ID
D003630 MESH_DESCRIPTOR_UI
7063 IUPHAR_LIGAND_ID
2257 INN_ID
ZS7284E0ZP UNII
1364321 RXNORM
11753 MMSL
4538 MMSL
d00205 MMSL
002662 NDDF
004821 NDDF
108790000 SNOMEDCT_US
35300007 SNOMEDCT_US
372715008 SNOMEDCT_US
65972004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9550 INJECTION 5 mg INTRAVENOUS NDA 21 sections
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9551 INJECTION 5 mg INTRAVENOUS NDA 21 sections
daunorubicin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0703-5233 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42658-019 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 22 sections
Daunorubicin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42658-021 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 22 sections
VYXEOS HUMAN PRESCRIPTION DRUG LABEL 2 68727-745 INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 44 mg INTRAVENOUS NDA 28 sections